Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous ocrelizumab in multiple sclerosis
2020-005448-48Phase 3Active
- Sponsor
- Roche
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ocrelizumab in multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) (2 arms), sponsored by Roche. Primary endpoint: Serum ocrelizumab area under the concentration-time curve from Week 1 to Week 12. Started May 2021; status: active.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2020-005448-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005448-48.